CONTEXT: Impairments in the pituitary-gonadal axis with aging are associated with loss of muscle mass and function and accumulation of upper body fat. OBJECTIVES: We tested the hypothesis that physiological supplementation with testosterone and GH together improves body composition and muscle performance in older men. DESIGN, SETTING, AND PARTICIPANTS: One hundred twenty-two community-dwelling men 70.8 +/- 4.2 yr of age with body mass index of 27.4 +/- 3.4 kg/m2, testosterone of 550 ng/dl or less, and IGF-I in lower adult tertile (< or =167 ng/dl) were randomized to receive transdermal testosterone (5 or 10 g/d) during a Leydig cell clamp plus GH (0, 3, or 5 microg/kg . d) for 16 wk. MAIN OUTCOME MEASURES: Body composition by dual-energy x-ray absorptiometry, muscle performance, and safety tests were conducted. RESULTS:Total lean body mass increased (1.0 +/- 1.7 to 3.0 +/- 2.2 kg) as did appendicular lean tissue (0.4 +/- 1.4 to 1.5 +/- 1.3 kg), whereas total fat mass decreased by 0.4 +/- 0.9 to 2.3 +/- 1.7 kg as did trunk fat (0.5 +/- 0.9 to 1.5 +/- 1.0 kg) across the six treatment groups and by dose levels for each parameter (P < or = 0.0004 for linear trend). Composite maximum voluntary strength of upper and lower body muscles increased by 14 +/- 34 to 35 +/- 31% (P < 0.003 in the three highest dose groups) that correlated with changes in appendicular lean mass. Aerobic endurance increased in all six groups (average 96 +/- 137 sec longer). Systolic and diastolic blood pressure increased similarly in each group with mean increases of 12 +/- 14 and 8 +/- 8 mm Hg, respectively. Other predictable adverse events were modest and reversible. CONCLUSIONS:Supplemental testosterone produced significant gains in total and appendicular lean mass, muscle strength, and aerobic endurance with significant reductions in whole-body and trunk fat. Outcomes appeared to be further enhanced with GH supplementation.
RCT Entities:
CONTEXT: Impairments in the pituitary-gonadal axis with aging are associated with loss of muscle mass and function and accumulation of upper body fat. OBJECTIVES: We tested the hypothesis that physiological supplementation with testosterone and GH together improves body composition and muscle performance in older men. DESIGN, SETTING, AND PARTICIPANTS: One hundred twenty-two community-dwelling men 70.8 +/- 4.2 yr of age with body mass index of 27.4 +/- 3.4 kg/m2, testosterone of 550 ng/dl or less, and IGF-I in lower adult tertile (< or =167 ng/dl) were randomized to receive transdermal testosterone (5 or 10 g/d) during a Leydig cell clamp plus GH (0, 3, or 5 microg/kg . d) for 16 wk. MAIN OUTCOME MEASURES: Body composition by dual-energy x-ray absorptiometry, muscle performance, and safety tests were conducted. RESULTS: Total lean body mass increased (1.0 +/- 1.7 to 3.0 +/- 2.2 kg) as did appendicular lean tissue (0.4 +/- 1.4 to 1.5 +/- 1.3 kg), whereas total fat mass decreased by 0.4 +/- 0.9 to 2.3 +/- 1.7 kg as did trunk fat (0.5 +/- 0.9 to 1.5 +/- 1.0 kg) across the six treatment groups and by dose levels for each parameter (P < or = 0.0004 for linear trend). Composite maximum voluntary strength of upper and lower body muscles increased by 14 +/- 34 to 35 +/- 31% (P < 0.003 in the three highest dose groups) that correlated with changes in appendicular lean mass. Aerobic endurance increased in all six groups (average 96 +/- 137 sec longer). Systolic and diastolic blood pressure increased similarly in each group with mean increases of 12 +/- 14 and 8 +/- 8 mm Hg, respectively. Other predictable adverse events were modest and reversible. CONCLUSIONS: Supplemental testosterone produced significant gains in total and appendicular lean mass, muscle strength, and aerobic endurance with significant reductions in whole-body and trunk fat. Outcomes appeared to be further enhanced with GH supplementation.
Authors: D R Taaffe; L Pruitt; J Reim; R L Hintz; G Butterfield; A R Hoffman; R Marcus Journal: J Clin Endocrinol Metab Date: 1994-11 Impact factor: 5.958
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Chevon M Rariy; Sarah J Ratcliffe; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; John Robbins; Joseph M Zmuda; Tamara B Harris; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: Qianning Jiao; Anne M Pruznak; Danuta Huber; Thomas C Vary; Charles H Lang Journal: Am J Physiol Endocrinol Metab Date: 2009-09-15 Impact factor: 4.310
Authors: Chad M Kerksick; Colin D Wilborn; Michael D Roberts; Abbie Smith-Ryan; Susan M Kleiner; Ralf Jäger; Rick Collins; Mathew Cooke; Jaci N Davis; Elfego Galvan; Mike Greenwood; Lonnie M Lowery; Robert Wildman; Jose Antonio; Richard B Kreider Journal: J Int Soc Sports Nutr Date: 2018-08-01 Impact factor: 5.150
Authors: Stephen E Borst; Joshua F Yarrow; Christine F Conover; Unyime Nseyo; John R Meuleman; Judyta A Lipinska; Randy W Braith; Darren T Beck; Jeffrey S Martin; Matthew Morrow; Shirley Roessner; Luke A Beggs; Sean C McCoy; Darryl F Cannady; Jonathan J Shuster Journal: Am J Physiol Endocrinol Metab Date: 2013-12-10 Impact factor: 4.310
Authors: Kerry L Hildreth; Daniel W Barry; Kerrie L Moreau; Joseph Vande Griend; Randall B Meacham; Tammie Nakamura; Pamela Wolfe; Wendy M Kohrt; J Mark Ruscin; John Kittelson; M Elaine Cress; Robert Ballard; Robert S Schwartz Journal: J Clin Endocrinol Metab Date: 2013-03-26 Impact factor: 5.958
Authors: Shalender Bhasin; E Jiaxiu He; Miwa Kawakubo; E Todd Schroeder; Kevin Yarasheski; Gregory J Opiteck; Alise Reicin; Fabian Chen; Raymond Lam; Jeffrey A Tsou; Carmen Castaneda-Sceppa; Ellen F Binder; Stanley P Azen; Fred R Sattler Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958